The recent NIV and NHG guidelines recommend SGLT2 inhibitors for the reduction of CKD progrend CV risk in patients with CKD associated with T2D with a very high risk for CV diseases [9]. The gene discussed is SLC5A2; the disease is chronic kidney disease.